Haleon Completes Deal To Grow Stake In China JV

Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.

Business_China
The deal offers access to China for Alvotech’s biosimilars portfolio • Source: Shutterstock

Haleon has completed a deal to boost its stake in its Chinese OTC joint venture, Tianjin TSKF Pharmaceutical.

The UK-based consumer health specialist has invested around £0.5bn ($0.6bn) to acquire an additional 33% equity interest in TSKF

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Geography

OTCs Are ‘Beacon Of Hope’ For Austrian Pharmacy

 
• By 

Just under half of Austrian pharmacists surveyed by Elpato Medien are “convinced that the OTC business will ensure the survival of their pharmacy.”

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By 

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.

Over The Counter: Brands, Brexit And New Self-Care Business Models, With PAGB’s Michelle Riddalls

 
• By 

HBW Insight catches up with UK OTC industry association CEO Michelle Riddalls to talk about digital self-care and the unrealized promise of Brexit - part 2.